GLP-1 and Kidney Protection: The FLOW Trial Unveiled

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

The FLOW trial demonstrated that semaglutide significantly reduces the risk of major kidney outcomes and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. This finding establishes GLP-1 receptor agonists as crucial agents for renoprotection, extending their benefits beyond glycemic and cardiovascular improvements.

GLP-1 and Kidney Protection: FLOW Trial Explained

The landscape of diabetes management has been profoundly reshaped by the discovery of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs). While their benefits in glycemic control and cardiovascular protection are well-established, the recent FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial has solidified their critical role in kidney protection. This trial provides compelling evidence that semaglutide, a prominent GLP-1 RA, offers substantial benefits for patients with type 2 diabetes and chronic kidney disease (CKD), addressing a significant unmet medical need.

The FLOW trial was a large-scale, randomized, double-blind, placebo-controlled study designed specifically to assess the kidney outcomes of semaglutide in patients with type 2 diabetes and CKD. It enrolled over 3,500 participants and was stopped early in October 2023 due to clear evidence of benefit, a strong indicator of its positive findings. The primary composite endpoint included major adverse kidney events: onset of kidney failure, a sustained decline of at least 50% in estimated glomerular filtration rate (eGFR), or death from kidney or cardiovascular causes. The results, presented in 2024, showed that semaglutide significantly reduced the risk of this primary composite endpoint by 24% compared to placebo (Hazard Ratio 0.76; 95% CI, 0.66 to 0.88; P=0.0003) [Mann et al., 2024].

This reduction in kidney events is particularly impactful given the progressive nature of diabetic kidney disease, which often leads to end-stage kidney disease (ESKD) requiring dialysis or transplantation. The trial demonstrated that semaglutide reduced the risk of ESKD by 21% and the risk of a sustained 50% eGFR decline by 27%. Furthermore, semaglutide also showed a significant reduction in cardiovascular death by 29%, reinforcing the interconnectedness of kidney and cardiovascular health. These numbers are not merely statistical; they represent a tangible improvement in the lives of patients at high risk of kidney failure and associated complications.

The mechanisms underlying GLP-1 RA-mediated kidney protection are thought to be multifactorial. Beyond their well-known effects on glycemic control and weight loss, GLP-1 RAs may exert direct renoprotective effects. These include reductions in intraglomerular pressure, improvements in renal hemodynamics, and anti-inflammatory and anti-fibrotic actions within the kidney. By reducing hyperglycemia, blood pressure, and body weight, semaglutide indirectly alleviates stress on the kidneys. Unlike SGLT2 inhibitors, which also offer significant kidney protection, GLP-1 RAs appear to work through distinct yet complementary pathways, suggesting potential additive benefits when used in combination.

It's important to understand that the FLOW trial specifically focused on semaglutide, and while other GLP-1 RAs have shown some evidence of kidney benefits, the robust and dedicated nature of the FLOW trial provides the strongest evidence to date for this class of medication in renoprotection. This trial has led to an expanded indication for subcutaneous semaglutide (Ozempic) by the FDA in January 2025, specifically to reduce the risk of sustained eGFR decline, ESKD, and cardiovascular death in adults with type 2 diabetes and CKD. You'll find that this will likely change clinical practice guidelines, making GLP-1 RAs a cornerstone of kidney-protective strategies.

While the benefits are clear, it's crucial to consider the clinical nuance. Patients with advanced CKD were included, but careful monitoring of kidney function remains essential. Some patients may experience gastrointestinal side effects, which are generally manageable with dose titration. The long-term adherence to these medications is also a factor, as continuous use is necessary to maintain the protective effects. Don't assume that all patients will respond identically; individualized assessment and management are key.

The practical takeaway from the FLOW trial is that semaglutide offers a powerful and proven strategy for kidney protection in patients with type 2 diabetes and CKD. This is a significant advancement, providing clinicians with another vital tool to slow the progression of kidney disease and improve overall patient outcomes. Don't overlook the importance of these findings; they underscore the comprehensive benefits of GLP-1 RAs, extending their impact from metabolic and cardiovascular health to critical renal preservation.